Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

RNA-binding as a new paradigm for androgen receptor-mediated prostate cancer therapeutic resistance

Award Number: R01CA301628
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2025
PERIOD OF PERFORMANCE END DATE: 03/31/2030

Group Awards By:

View Award Description

RNA-binding as a new paradigm for androgen receptor-mediated prostate cancer therapeutic resistance - Project Summary Given that prostate cancer is primarily driven by androgen receptor (AR) signaling, AR-targeting therapies have been the mainstay treatment for advanced prostate cancer. However, despite the advent of second- generation potent AR-pathway inhibitors such as enzalutamide, apalutamide, and abiraterone, disease progression after AR-targeting therapies remains a major challenge. AR reactivation drives disease progression in at least 70% of cases. AR can be reactivated through multiple mechanisms, with AR gene amplification and/or overexpression being particularly common. Understanding how AR resists these therapies is crucial for devising strategies to delay or prevent progression to incurable stages. The proposed study addresses this urgent need. Our preliminary studies have uncovered a novel role for AR in enhancing splicing fidelity, extending beyond its classical transcriptional activity. We also discovered that AR possesses potent RNA-binding activity, which is not impacted by current AR-targeting therapies, including enzalutamide. The overlap between AR’s RNA and DNA targets is limited. Instead, AR binds to the transcripts of over 130 splicing factors and positively regulates the expression of many of these post-transcriptionally. This regulation is consistent with the elevated levels of these splicing factors during disease progression. We hypothesize that AR binds splicing factor (and other) pre-mRNAs to promote the expression of key splicing factors, leading to efficient splicing and expression of genes critical for prostate cancer progression and resistance to AR-targeting therapies. This hypothesis will be tested through two specific aims utilizing clinically relevant model systems and clinical datasets. Aim 1 will elucidate the impact of AR-RNA interactions in prostate cancer progression and resistance to AR-targeting therapies. Aim 2 will determine the mechanisms by which AR regulates pre-mRNA splicing. Decades of research on AR have predominantly focused on its DNA-binding activity. The outcome from this study could transform our understanding of AR’s functions and its molecular contributions to prostate cancer progression and therapeutic resistance. It could also radically change the way we think about targeting AR for effective management of prostate cancer.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $632,906 )
2026	2026	THE ADMINISTRATORS OF TULANE EDUCATIONAL FUND	6823 SAINT CHARLES AVE	NEW ORLEANS	LA	70118	ORLEANS	USA	Cancer Biology Research	000	2	3/2/2026	NON-COMPETING CONTINUATION	$632,906
														Subtotal = $632,906

Issue Date FY: 2025 ( Subtotal = $632,906 )
2025	2025	THE ADMINISTRATORS OF TULANE EDUCATIONAL FUND	6823 SAINT CHARLES AVE	NEW ORLEANS	LA	70118	ORLEANS	USA	Cancer Biology Research	000	1	3/26/2025	NEW	$632,906
														Subtotal = $632,906

Grand Total All Awards = $1,265,812

Top

All Categories

About

Search

Reports

Data Submission

Award Information

RNA-binding as a new paradigm for androgen receptor-mediated prostate cancer therapeutic resistance

Award Number: R01CA301628

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2025

PERIOD OF PERFORMANCE END DATE: 03/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer